Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Abstract

Background-Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and the risk of stent thrombosis between the Resolute zotarolimus-eluting stent (R-ZES) and the everolimus-eluting stent (EES). The aim of this study was to evaluate the safety and efficacy of the R-ZES compared with EES in patients undergoing percutaneous coronary intervention. Methods and Results-A systematic literature search of electronic resources was performed using specific search terms until September 2014. Random-effects meta-analysis was performed comparing clinical outcomes between patients treated with R-ZES and EES up to maximum available follow-up. The primary efficacy end point was targetvessel revascularization.

Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

“…Several studies including two randomized clinical trials, which directly compared EES and R-ZES, showed similar efficacy and safety of these 2 stents in all-comers and in complex patients. [12][13][14][15][16]. While a previous study suggested an interaction between stent type (EES vs. R-ZES) and diabetes [13], more recent study demonstrated that EES and R-ZES had similar clinical outcomes in patients with DM [17].…”

Five-year clinical performance of a biodegradable polymer-coated biolimus-eluting stent in unselected patients

“…Along the same lines, the 2-year follow-up of the Nobori Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial trial confirmed the non-inferiority of the BP-BES compared with the everolimus-eluting stent 19. Taken together, these data support the short-term and long-term equivalence of the BP-BES with durable polymer everolimus-eluting stents, which currently represent the benchmark of safety and efficacy among DES 20 21…”

Coronary Microvascular Obstruction

“…Moreover, 23% restenosis rate seems rather high compared with usually reported rates in new-generation drug-eluting stents. 11,12 Identifying patients at increased risk of in-stent restenosis or stent thrombosis is particularly important to guide management of STEMI patients. Established predictors include patient characteristics, lesion complexity, and mechanical factors (eg, stent length or underexpansion).…”